

<p>Age Indications for MCV4 (serotype ACWY) Vaccines</p> <p>Menactra® (Sanofi Pasteur): for aged 9 months through 55 years MENVEO® (Novartis): for aged 2 months through 55 years</p> <p>Indications for Use and Schedule</p> <ul style="list-style-type: none"> · Routinely administer: <ul style="list-style-type: none"> - One dose at aged 11-12 years¹; 2nd dose at age 16 years - Preferred for ages 56 years & older who previously received MCV4 or who are recommended to receive multiple doses of meningococcal vaccine* · Adolescent catch-up schedule: <ul style="list-style-type: none"> - If 1st dose given at aged 13 through 15 years, give a 2nd dose at aged 16 through 18 years² - If 1st dose given at age 16 years or older, a 2nd dose is <u>not</u> recommended · Minimum Interval <ul style="list-style-type: none"> - 8 weeks between 2 doses for all ages 	<p>Vaccine Administration</p> <ul style="list-style-type: none"> · Intramuscular (IM) injection in the deltoid of the arm <ul style="list-style-type: none"> - 1-1.5 inch, 22-25 gauge needle · Use professional judgment in selecting needle length · Give simultaneously with all vaccines <u>with this exception</u>: <ul style="list-style-type: none"> - If using Menactra® for asplenic persons, ensure PCV13³ is given first and then Menactra at least 4 weeks later⁴ <p>Storage and Handling</p> <ul style="list-style-type: none"> · Store in the refrigerator between 35°-46° F (2°-8° C); Do NOT freeze · Stand-alone storage units are preferred · Keep in the original box: Do Not freeze · Menactra is ready to use; shake well · MENVEO must be reconstituted <ul style="list-style-type: none"> - Draw up MenCYW liquid (diluent) - Add to Men A vial; invert; shake well · Administer vaccines immediately after drawn up in syringe
--	--



***PERSONS WITH CERTAIN MEDICAL OR OTHER RISK CONDITIONS**

- Persons aged 11 years & older with persistent terminal complement deficiency or asplenia (functional or anatomic):
 - 2 dose primary series (0, 2 months) & a booster dose every 5 years thereafter
- Persons aged 11 years & older who are at increased risk due to prolonged exposure (e.g., travel to/living in endemic areas, current outbreak, microbiologists exposed to *N. meningitidis*) or when required (e.g., military recruits, travel to Mecca during annual Hajj):
 - Give 1 dose; if the person remains at increased risk, a booster dose is recommended 5 years later
- Persons with HIV and an indication for vaccination should receive a 2-dose primary series (0, 2 months):
 - Need and interval for booster dose determined by risk factor
 - HIV without another risk factor present, is not a medical indication for meningococcal vaccination
- Ensure students age 21 years or younger who are entering college/living in dorm have received a dose of MCV4 in the last 5 years
 - Consider 1 dose of MCV4 for students age 21 years or younger who are currently attending college, with no dose in the last 5 years
 - MCV4 is not routinely recommended for a healthy person age 22 years or older

CONTRAINDICATIONS

- An anaphylactic (severe allergic) reaction to a prior dose or a component of MCV4 vaccine

PRECAUTIONS

- Moderate to severe acute illness with or without fever

FURTHER POINTS

- Both MCV4 vaccines protect against serotype A, C, W, Y; **Serotype B is not in either vaccine; Meningococcal B (MenB) vaccines protect against B**
- Persons indicated for a 2-dose primary series who previously received only 1 dose of MCV4, should get a 2nd dose of MCV4 as soon as feasible; forecast the booster dose (if applicable) from the date of the 2nd primary series dose
- Persons aged 56 years or older who have never received a meningococcal vaccine and anticipate needing only one dose, MPSV4 (meningococcal polysaccharide vaccine) is preferred
- Persons who inadvertently receive MPSV4 should be revaccinated with MCV4 using a minimum interval of 8 weeks
- Meningococcal Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>

¹If a MCV4 dose is given at age 10 years, will count as the age 11-12 years/1st dose of the adolescent series; give next dose at age 16 years

²Recommended interval is 3-5 years but if unlikely to return at later date, give 2nd dose at age 16 years and at least 8 weeks after last dose

³PCV13 is Pneumococcal Conjugate Vaccine; ensure at least one dose of PCV13 (Prenar13[®]) is given to all persons with asplenia

⁴ For persons aged 2 years or older with asplenia, give the PCV13 dose 1st and wait 4 weeks before giving Menactra (MCV4-D). Menveo (MCV4-CRM) can be given at the same time or at any interval before/after PCV13.

Resources: "Prevention and Control of Meningococcal Disease, Recommendations of the ACIP", March 22, 2013, located at www.cdc.gov/vaccines/recs.